• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002262.SZ
Share

Jiangsu Nhwa Pharmaceutical Co., LTD Stocks

CN¥ 20Last Updated 26.05.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

CN¥ 3.03B

CN¥ 20
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Jiangsu Nhwa Pharmaceutical Co., LTD produces and sells central nervous system drugs, and cardiovascular and cerebrovascular drugs in China and internationally. The company offers drugs in the anesthesia, psychiatry, and neurological categories. It also provides APIs in the areas of central nervous system, anesthetic and sedative, and others. The company was founded in 1978 and is headquartered in Xuzhou, China.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 002262.SZ is 27 and suggests 32% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.05.2026 12:53

Meta has started selling AI subscriptions to chatbot and social networks. The shares jumped by 4%

28.05.2026 12:24

Boeing called China's order for 200 airplanes the "first tranche." The market was disappointed with it

28.05.2026 11:00

Oil jumped 4% after the exchange of blows between the U.S. and Iran. What's in the markets?

28.05.2026 10:19

Top stories for the morning: oil rises on US and Iran strikes, Dell gets Pentagon contract

28.05.2026 07:00

The founder of Yardeni is not expecting a market bubble. He named the main driver of the year

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026